NCT01600274已完成不适用
Characterisation of Relative Bioavailability and Assessment of Bioequivalence of a Newly Developed Ethinylestradiol/Dienogest IR Formulation in Comparison With a Marketed Reference Product (Valette®)
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- AUC0-tlast of EE and DNG after each treatment
研究概览
简要总结
- Characterisation of relative bioavailability of Diena (Test) in comparison to Valette® (Reference) after single dose administration under fasting conditions
- Assessment of bioequivalence of Test vs. Reference after single dose administration under fasting conditions, determined by use of area under the concentration time curve AUC0-tlast and maximum concentration Cmax obtained for ethinylestradiol (EE) and dienogest (DNG)
- Descriptive characterisation of safety and tolerability of the investigational products in the study population
详细描述
The aims of this study were to characterise relative bioavailability of Diena (Test) in comparison to Valette® (Reference) after single dose administration under fasting conditions and to assess bioequivalence of Test vs. Reference after single dose administration under fasting conditions, determined by use of area under the concentration time curve AUC0-tlast and maximal concentration Cmax obtained for ethinylestradiol (EE) and dienogest (DNG). Furthermore, a descriptive characterisation of safety and tolerability of the investigational products in the study population was performed.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- Female
- 接受健康志愿者
- 是
入选标准
- •sex: female
- •ethnic origin: Caucasian
- •age: 18 - 55 years, inclusive
- •body-mass index (BMI): more than 19 kg/m² and less than 27 kg/m²
- •good state of health
- •non-smoker or an ex-smoker for a least 6 months
- •written informed consent, after having been informed about benefits and potential risks of the trial, as well as details of the insurance taken out to cover the subject's participating in the study
排除标准
- •Subjects cannot be included if they match any of the following exclusion criteria:
- •Safety concerns
- •existing cardiac or haematological diseases and/or pathological findings, which might interfere with the safety, tolerability, absorption and/or pharmacokinetics of the active ingredient
- •existing hepatic and/or renal diseases and/or pathological findings, which might interfere with the safety, tolerability, absorption and/or pharmacokinetics of the active ingredient
- •existing gastrointestinal diseases and/or pathological findings, which might interfere with the safety, tolerability, absorption and/or pharmacokinetics of the active ingredient
- •history of relevant CNS and/or psychiatric disorders and/or currently treated CNS and/or psychiatric disorders
- •pathological ECG (12 standard leads) which might interfere with the safety of the active ingredient
- •known allergic reactions to the active ingredients used or to constituents of the pharmaceutical preparations
- •subjects with severe allergies or multiple drug allergies
- •systolic blood pressure > 160 mmHg
- •diastolic blood pressure > 90 mmHg
- •heart rate < 45 and > 100 bpm
- •laboratory values out of normal range unless the deviation from normal is judged as not relevant for the study by the investigator
- •positive anti-HIV-test, HBs-AG-test or anti-HCV-test
- •presence or history of venous or arterial thrombosis (e.g. deep venous thrombosis, pulmonary embolism, myocardial infarction and prodromal conditions (e.g. transient ischaemic attack, angina pectoris)), predisposition for venous or arterial thrombosis (e.g. APC-resistance, antithrombin-III-deficiency, protein C deficiency, protein S deficiency or other thrombogene coagulopathy, heart valve disorders or thrombogene cardiac dysrhythmias)
- •presence or history of liver tumours or known or suspected sex-hormone influenced malignancies (e.g. of the breasts or endometrium)
- •unclarified vaginal bleeding or amenorrhoe
- •subjects with fructose or galactose intolerance, deficiency of lactase, saccharase-isomaltase or malabsortion of glucose/galactose Lack of suitability for the trial
- •acute or chronic diseases which could affect absorption or metabolism
- •history of or current drug or alcohol dependence
- •regular intake of alcoholic food or beverages of ≥ 20 g per day
- •subjects who are on a diet which could affect the pharmacokinetics of the active ingredient
- •regular intake of caffeine containing food or beverages of ≥ 500 mg per day
- •blood donation or other blood loss of more than 400 ml within the last two months prior to individual enrolment of the subject
- •participation in a clinical trial during the last two months prior to individual enrolment of the subject
- •regular treatment with any systemically available medication (except usual replacement therapy with L-thyroxine)
- •subjects, who report a frequent occurrence of migraine attacks
- •use of hormonal preparations within 6 weeks (oral, transdermal, vaginal), 2 months (intramuscularly administered depot preparations used once per month) or 6 months (intramuscularly administered depot preparations used once per 3 month) before pre-study examination
- •For female subjects with childbearing potential only:
- •positive pregnancy test at pre-study examination
- •pregnant or lactating women
- •female subjects who do not agree to apply adequate non-hormonal and highly effective contraceptive methods as defined in Note for Guidance on Non-Clinical Safety Studies for the Conduct of Human Clinical Trials for Pharmaceuticals (CPMP/ICH/286/95, modification), November 2000 Administrative reasons
- •subjects suspected or known not to follow instructions
- •subjects who are unable to understand the written and verbal instructions, in particular regarding the risks and inconveniences they will be exposed to during their participation in the study The exclusion criteria are chosen to assure that subjects with specific risks for administration of the investigated medicinal products and subjects with conditions, which may have an impact on pharmacokinetic parameters, cannot be included.
研究组 & 干预措施
Diena
Experimental
Dienogest-Ethinyl Estradiol (test product) tablet
干预措施: Dienogest-Ethinyl Estradiol (test product) (Drug)
Valette®
Active Comparator
Dienogest-Ethinyl Estradiol (reference product) tablet
干预措施: Dienogest-Ethinyl Estradiol (reference product) (Drug)
结局指标
主要结局
AUC0-tlast of EE and DNG after each treatment
时间窗: PK blood sampling will be performed pre-dose (within 1.5 h prior to administration) as well as 0.25, 0.5, 0.75, 1, 1.33, 1.67, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 18, 24, 36, 48 and 60 h p.a.
Cmax of EE and DNG after each treatment
时间窗: PK blood sampling will be performed pre-dose (within 1.5 h prior to administration) as well as 0.25, 0.5, 0.75, 1, 1.33, 1.67, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 18, 24, 36, 48 and 60 h p.a.
次要结局
- Clast of EE and DNG after each treatment(PK blood sampling will be performed pre-dose (within 1.5 h prior to administration) as well as 0.25, 0.5, 0.75, 1, 1.33, 1.67, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 18, 24, 36, 48 and 60 h p.a)
- AUCexpol% of EE and DNG after each treatment(PK blood sampling will be performed pre-dose (within 1.5 h prior to administration) as well as 0.25, 0.5, 0.75, 1, 1.33, 1.67, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 18, 24, 36, 48 and 60 h p.a)
- Tmax of EE and DNG after each treatment(PK blood sampling will be performed pre-dose (within 1.5 h prior to administration) as well as 0.25, 0.5, 0.75, 1, 1.33, 1.67, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 18, 24, 36, 48 and 60 h p.a)
- t1/2 of EE and DNG after each treatment(PK blood sampling will be performed pre-dose (within 1.5 h prior to administration) as well as 0.25, 0.5, 0.75, 1, 1.33, 1.67, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 18, 24, 36, 48 and 60 h p.a)
- MRT of EE and DNG after each treatment(PK blood sampling will be performed pre-dose (within 1.5 h prior to administration) as well as 0.25, 0.5, 0.75, 1, 1.33, 1.67, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 18, 24, 36, 48 and 60 h p.a)
- Tlag of EE and DNG after each treatment(PK blood sampling will be performed pre-dose (within 1.5 h prior to administration) as well as 0.25, 0.5, 0.75, 1, 1.33, 1.67, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 18, 24, 36, 48 and 60 h p.a)
- λ of EE and DNG after each treatment(PK blood sampling will be performed pre-dose (within 1.5 h prior to administration) as well as 0.25, 0.5, 0.75, 1, 1.33, 1.67, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 18, 24, 36, 48 and 60 h p.a)
- AUC0-∞ of EE and DNG after each treatment(PK blood sampling will be performed pre-dose (within 1.5 h prior to administration) as well as 0.25, 0.5, 0.75, 1, 1.33, 1.67, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 18, 24, 36, 48 and 60 h p.a)
- tlast of EE and DNG after each treatment(PK blood sampling will be performed pre-dose (within 1.5 h prior to administration) as well as 0.25, 0.5, 0.75, 1, 1.33, 1.67, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 18, 24, 36, 48 and 60 h p.a)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Characterisation of Relative Bioavailability With Bioequivalence Assessment of Deferiprone Tablets After Oral Single Dose AdministrationBioequivalenceNCT02980458SocraTec R&D GmbH25
已完成
不适用
Bioequivalence Study of Metformin Hydrochloride 1000mg Tablets Under Fed ConditionsHealthyNCT00778466Ranbaxy Laboratories Limited32
已完成
不适用
Bioequivalence Study of Metformin Hydrochloride 1000mg Tablets Under Fasting ConditionsHealthyNCT00778427Ranbaxy Laboratories Limited32
进行中（未招募）
1 期
Relative bioavailability and comparative pharmacokinetics (blood levels of the drug) of 13-CRA oral liquid and capsule formulations: a randomised, open label, multi-dose, cross-over clinical trial in children requiring treatment cycles of 13-CRA.euroblastomaMedDRA version: 20.0 Level: PT Classification code 10029260 Term: Neuroblastoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: HLT Classification code 10029212 Term: Nervous system neoplasms malignant NEC System Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.0 Level: HLGT Classification code 10029211 Term: Nervous system neoplasms malignant and unspecified NEC System Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.0 Level: SOC Classification code 10029104 Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps) System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-005104-25-GBova BioPharma Limited20
已完成
1 期
Relative Bioavailability of BI 201335 Capsule Versus Three Different Oral SolutionsHealthyNCT01764945Boehringer Ingelheim56